Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Moisture And Humidity Tips From DampRid May Aid Allergy Suffers
With one in five, or 60 million, Americans suffering from some kind of allergy, spring and summer can be a difficult time of year as pollen, moisture and humidity increase. According to the Asthma and Allergy Foundation of America, allergies are considered the fifth leading chronic disease and are a major cause of work absenteeism, resulting in nearly four million missed or lost workdays each year.
generic viagra online
Rising Lifestyle Illnesses And Potential Swine Flu Catastrophe For Indigenous Populations
The first of two reviews in this week"s edition of The Lancet discusses the standards of health and lifestyles of Indigenous people. It is the work of Professor Michael Gracey, of the Unity of First People of Australia, Perth, WA, Australia, and Professor Malcolm King, of the University of Alberta, Edmonton, Canada. There are almost 400 million Indigenous people in the world with low standards of health that are usually linked to malnutrition, poverty, environmental contamination, and prevalent infections. However, as those people shift to more modern or "western" lifestyles, conditions such as obesity, cardiovascular diseases, and type 2 diabetes have been on the rise. Physical, social and mental disorders related to misuse of alcohol and other drugs are also increasing. Indigenous people must be encouraged and given the means to take responsibility for issues that affect their health. In this review, the authors discuss indigenous people worldwide but focus on Aboriginal Australians.
News of the day
Treating Depression May Protect Against Insulin Resistance In Type 2 Diabetes Patients
US researchers found that treating depression may protect against insulin resistance observed in depression in patients at risk of type 2
Medical Devices

European Medicines Agency Recommends Withdrawal Of Dextropropoxyphene-Containing Medicines (Including Co-Proxamol)

The European Medicines Agency (EMEA) has today announced their recommendation to withdraw the marketing authorisations for dextropropoxyphene-containing medicines (including co-proxamol) across the European Union (EU). This recommendation was made after the Committee on Medicinal Products for Human Use (CHMP) concluded that the risks, particularly of potentially fatal overdose, were greater than the medicine"s benefits. The EMEA"s recommendation has been forwarded to the European Commission (EC) for a decision which will be legally binding across the EU. In the UK, the only medicine affected by the EMEA"s announcement is co-proxamol. The MHRA announced its decision to withdraw co-proxamol in 2005. Since then the vast majority of patients have managed to find an acceptable alternative, after consultation with their health care professional. Co-proxamol is a combination of a weak opioid (a weak painkiller), dextropropoxyphene (DXP), with a relatively low dose of paracetamol. There is no robust evidence that co-proxamol offers any advantage over other widely used painkillers, paracetamol or ibuprofen, at normal doses. Co-proxamol is extremely dangerous in overdose as only a small overdose can be fatal, and death can occur very rapidly - before medical attention can be sought. The MHRA does recognise that there is a small group of patients who have found it very difficult to change from co-proxamol, when alternatives appear not to be effective or suitable. We have worked with the manufacturer to ensure some unlicensed product remains available. As with any unlicensed medicine there is a provision for the supply of unlicensed co-proxamol, on the responsibility of the prescriber, who can judge the risks and benefits in consultation with the patient. A key part of the National Suicide Prevention Strategy is to reduce ready access to methods of suicide. Co-proxamol has been a significant cause of death from overdose, and its withdrawal has saved the lives of around 300 - 400 people per annum in the United Kingdom from self-poisoning, of which around a fifth were accidental. The MHRA welcomes the recent paper by Keith Hawton and colleagues highlighting the significant public health impact of the withdrawal of co-proxamol from the UK market. MHRA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009